Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study

Affiliations

• ¹ Research Institute and Comprehensive Center for Inflammation Medicine, University of Luebeck, Luebeck, Germany. Electronic address: diamant.thaci@uksh.de.
• ² Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
• ³ Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany.
• ⁴ Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
• ⁵ University of Texas Health Science Center and Center for Clinical Studies, Houston, Texas.
• ⁶ Dermatology Clinic, Tartu University Hospital, Department of Dermatology, University of Tartu, Tartu, Estonia.
• ⁷ Emek Medical Center, Afula, Israel.
• ⁸ Department of Dermatology, University of Frankfurt, Frankfurt am Main, Germany.
• ⁹ Dermatrials Research Inc, Hamilton, Canada; Venderm Innovations in Psoriasis, Hamilton, Canada.
• ¹⁰ Novartis Pharma AG, Basel, Switzerland.
• ¹¹ Novartis Beijing Novartis Pharma Co Ltd, Shanghai, China.
• ¹² Novartis Healthcare Pvt Ltd, Hyderabad, India.
• ¹³ Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
• ¹⁴ Oregon Medical Research Center, Portland, Oregon.